Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
31.27
-0.02 (-0.06%)
At close: Jun 5, 2026, 4:00 PM EDT
31.26
-0.01 (-0.03%)
After-hours: Jun 5, 2026, 7:53 PM EDT
Catalyst Pharmaceuticals Employees
Catalyst Pharmaceuticals had 182 employees as of December 31, 2025. The number of employees increased by 1 or 0.55% compared to the previous year.
Employees
182
Change (1Y)
1
Growth (1Y)
0.55%
Revenue / Employee
$3,279,989
Profits / Employee
$1,216,060
Market Cap
3.83B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 182 | 1 | 0.55% |
| Dec 31, 2024 | 181 | 14 | 8.38% |
| Dec 31, 2023 | 167 | 85 | 103.66% |
| Dec 31, 2022 | 82 | 6 | 7.89% |
| Dec 31, 2021 | 76 | 2 | 2.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Travere Therapeutics | 497 |
| Celcuity | 155 |
| Edgewise Therapeutics | 154 |
| Erasca | 103 |
| NewAmsterdam Pharma Company | 100 |
CPRX News
- 8 days ago - Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 8 days ago - Catalyst Pharmaceuticals Proxy statement: Proxy filing - Filings
- 24 days ago - Catalyst Pharmaceuticals Proxy statement: Proxy filing - Filings
- 25 days ago - Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c - TheFly
- 25 days ago - Catalyst Pharmaceuticals not providing forward-looking guidance - TheFly
- 25 days ago - Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 25 days ago - Catalyst Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 25 days ago - Catalyst Pharmaceuticals Earnings release: Q1 2026 - Filings